住院慢性乙型肝炎病毒感染患者抗病毒治疗现状调查

目的了解住院慢性乙型肝炎病毒感染患者的抗病毒治疗现状，为指导合理抗病毒治疗和优化抗病毒治疗方案提供依据。方法根据住院病历采集2013年1-6月于我院住院慢性乙型肝炎病毒感染患者抗病毒治疗情况，统计其抗病毒治疗率及其与患者特征间的关系。结果住院慢性乙型肝炎病毒感染患者共447例，符合抗病毒治疗适应证者422例，抗病毒治疗率为84.1%（355例），在全部治疗方案中恩替卡韦治疗的构成比最高（43.4%）。初治患者和经治患者抗病毒治疗率分别为79.6%和93.0%（P〈0.05），初治患者采用ADV、LAM单药治疗的比例高于经治患者，联合治疗（NA＋IFN或NAs）的比例低于经治患者（P〈0.05）。患者性别、年龄、病史、家族史及不同诊断之间抗病毒治疗率无显著差异（P〉0.05）。结论住院慢性乙型肝炎病毒感染患者抗病毒治疗正在逐渐规范化，但总体抗病毒治疗率仍需进一步提高。

Current Status of Antiviral Treatments in Inpatients Chronically Infected with Hepatitis B Virus

Objective To investigate the current status of antiviral therapy in inpatients chronically infected with hepatitis B virus, and provide evidence for reasonable guidance and optimization of antiviral therapy. Methods According to medical records, to collect the data of antiviral therapy of the inpatients with chronic hepatitis B virus infection in Qingdao Hospital for Infectious Diseases hospitalizied from January to June, 2013, and to analyze the rates of antiviral therapy and the relationships with the characteristics of patients. Results 447 inpatients with chronic hepatitis B virus infection were enrolled, among which 422 cases met the indications for antiviral therapy. The overall rate of antiviral therapy was 84.1%（355 cases）. In all the treatment regiments, the proportion of entecavir was the highest（43.4%）. The rates of current antiviral therapy in previously untreated patients and treated patients were 79.6 %and 93.0%（P〈0.05）, respectively. The proportions of monotherapy with adefovir dipivoxil or lamivudine were higher, and combination therapies（nucleost]ide analogue plus interferon or combination of nucleost]ide analogue） were lower in previously untreated patients than in treated patients（P〈0.05）. There were no significant difference of antiviral therapy rates between sex and family history or among the durations of disease, age and diagnosis of patients（P〉0.05）. Conclusion The antiviral therapy of inpatients with chronic hepatitis B virus infection is gradually standardized, but the overall rate of antiviral therapy needs to be further improved.